These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26670054)

  • 1. Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.
    Li J; Lu Z; Kong X; Ma Y; Zhang X; Bansal SS; Abbate V; Hider RC
    Future Med Chem; 2015; 7(18):2439-49. PubMed ID: 26670054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake.
    Ma Y; Roy S; Kong X; Chen Y; Liu D; Hider RC
    J Med Chem; 2012 Mar; 55(5):2185-95. PubMed ID: 22339047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values.
    Liu ZD; Piyamongkol S; Liu DY; Khodr HH; Lu SL; Hider RC
    Bioorg Med Chem; 2001 Mar; 9(3):563-73. PubMed ID: 11310590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.
    Liu ZD; Kayyali R; Hider RC; Porter JB; Theobald AE
    J Med Chem; 2002 Jan; 45(3):631-9. PubMed ID: 11806714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.
    Xie YY; Lu Z; Kong XL; Zhou T; Bansal S; Hider R
    Eur J Med Chem; 2016 Jun; 115():132-40. PubMed ID: 27014847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.
    Bebbington D; Dawson CE; Gaur S; Spencer J
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3297-300. PubMed ID: 12392736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
    Dehkordi LS; Liu ZD; Hider RC
    Eur J Med Chem; 2008 May; 43(5):1035-47. PubMed ID: 17869385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjugation to 4-aminoquinoline improves the anti-trypanosomal activity of Deferiprone-type iron chelators.
    Gehrke SS; Pinto EG; Steverding D; Pleban K; Tempone AG; Hider RC; Wagner GK
    Bioorg Med Chem; 2013 Feb; 21(3):805-13. PubMed ID: 23266185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, physicochemical properties, and evaluation of novel iron chelators with fluorescent sensors.
    Ma Y; Luo W; Quinn PJ; Liu Z; Hider RC
    J Med Chem; 2004 Dec; 47(25):6349-62. PubMed ID: 15566304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of hydroxypyridin-4-ones as orally active iron chelators.
    Hider RC; Singh S; Porter JB; Huehns ER
    Ann N Y Acad Sci; 1990; 612():327-38. PubMed ID: 2291561
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydrolytic and metabolic characteristics of the esters of 1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41), potentially useful iron chelators.
    Liu DY; Liu ZD; Lu SL; Hider RC
    Pharmacol Toxicol; 2000 May; 86(5):228-33. PubMed ID: 10862505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
    Liu ZD; Khodr HH; Lu SL; Hider RC
    J Pharm Pharmacol; 2000 Mar; 52(3):263-72. PubMed ID: 10757413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and iron(III) binding properties of 3-hydroxypyrid-4-ones derived from kojic acid.
    Molenda JJ; Basinger MA; Hanusa TP; Jones MM
    J Inorg Biochem; 1994 Aug; 55(2):131-46. PubMed ID: 8051541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhodamine labeling of 3-hydroxy-4-pyridinone iron chelators is an important contribution to target Mycobacterium avium infection.
    Moniz T; Nunes A; Silva AM; Queirós C; Ivanova G; Gomes MS; Rangel M
    J Inorg Biochem; 2013 Apr; 121():156-66. PubMed ID: 23384853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
    Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
    J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
    Liu ZD; Khodr HH; Liu DY; Lu SL; Hider RC
    J Med Chem; 1999 Nov; 42(23):4814-23. PubMed ID: 10579844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates.
    Turcot I; Stintzi A; Xu J; Raymond KN
    J Biol Inorg Chem; 2000 Oct; 5(5):634-41. PubMed ID: 11085654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of two isomeric beta-d-glucosiduronic acids derived from 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rat liver homogenate incubates.
    Liu DY; Liu ZD; Piyamongkol S; Lu SL; Hider RC
    J Pharm Pharmacol; 2002 Jul; 54(7):951-7. PubMed ID: 12162714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of orally active iron chelators.
    Hider RC; Choudhury R; Rai BL; Dehkordi LS; Singh S
    Acta Haematol; 1996; 95(1):6-12. PubMed ID: 8604587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.